## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.98 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($793.12)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Mckesson Corporation Announces Third Quarter Fiscal 2026 Earnings Release Date**
- Source: Business Wire | 20251222T130844 | Neutral | Relevance: 100%
- McKesson Corporation will release its third-quarter fiscal 2026 financial results after market close on Wednesday, February 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results, which will be available on its Investor Relations website. McKesson is a diversified healthcare services leader committed to improving health outcomes.

**2. McKesson (MCK) Valuation Check as Shares Tick Higher on Optimism Ahead of Earnings**
- Source: Simply Wall Street | 20251221T140830 | Bullish | Relevance: 100%
- McKesson (MCK) shares have risen by 1% as traders anticipate strong earnings, driven by optimism over the company's momentum and significant share price growth. Despite hovering near record highs, the stock is considered 12.7% undervalued according to a narrative fair value near $939, fueled by investments in digitization and automation that are expected to improve operational efficiency and net margins. However, potential risks include heightened regulatory pressure on drug pricing and vertical integration that could impact wholesale economics.

**3. McKesson Corporation: FY26 Earnings Visibility Underpins Buy Case (NYSE:MCK)**
- Source: Seeking Alpha | 20251222T232643 | Bullish | Relevance: 100%
- McKesson Corporation is undervalued despite strong revenue growth, margin expansion, and capital returns, leading to a "Buy" rating with a $920 target price, reflecting a 13.5% upside. The company's strategy involves boosting margins through high-margin oncology and multispecialty growth while divesting lower-margin medical-surgical solutions. Strong Q2 results, low leverage, and planned aggressive share buybacks further support the investment thesis.

**4. McKesson Stock: I Expect A Significant Slowdown In 2026 (NYSE:MCK)**
- Source: Seeking Alpha | 20251221T152830 | Bearish | Relevance: 100%
- McKesson experienced impressive growth in 2025, driven by GLP-1 drug tailwinds, but this momentum is expected to fade, leading to a significant slowdown in 2026. Despite strong top-line growth, the company's margin profile remains lackluster, and its valuation at 21x forward earnings suggests potential multiple contraction. The author maintains a bearish outlook on the stock.

**5. Wedge Capital Management L L P NC Reduces Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251221T123523 | Somewhat-Bullish | Relevance: 97%
- Wedge Capital Management L L P NC reduced its stake in McKesson Corporation (NYSE:MCK) by 18.0% in the third quarter of 2025, selling 7,948 shares and ending with 36,114 shares valued at $27.9 million. Despite this reduction, other large institutional investors increased their holdings, and McKesson reported strong quarterly earnings, beating EPS estimates and announcing a quarterly dividend. Analysts have a consensus "Moderate Buy" rating with a target price of $892.86.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.7B |
| Beta | 0.38 |
| 52W Range | $565.75 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 18.8 |
| Current P/E | 21.3 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.0% (minimal 5-day change). Below STRENGTH zone by 5.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). RSI neutral at 51. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.03% (CS: 43) | Neutral |
| RSI_14 | 51.3 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.000x | Below |
| vs SMA200 | 1.125x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $825.62
- **Stop Loss:** $793.12 (3.9% risk)
- **Target:** $890.62 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 36
- **Position Value:** $29,722.32
- **Portfolio %:** 29.72%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*